AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
197.78
-0.63 (-0.32%)
At close: 4:00PM EDT

198.00 +0.22 (0.11%)
Pre-Market: 8:48AM EDT

Stock chart is not supported by your current browser
Previous Close198.41
Open199.01
Bid197.25 x 100
Ask198.30 x 200
Day's Range197.30 - 203.95
52 Week Range184.50 - 256.80
Volume5,097,533
Avg. Volume2,482,572
Market Cap66.12B
Beta1.26
PE Ratio (TTM)6.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (1.41%)
Ex-Dividend Date2017-08-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com14 hours ago

    Cramer: Getting Out the Bad News Gives a Post-Earnings Boost

    When management gets ahead of bad news, it allows a stock to prosper when the company reports earnings.

  • Reuters15 hours ago

    Allergan ruling casts doubt on tribal patent strategy

    In a deal announced last month, Allergan transferred the Restasis patents to New York state's Saint Regis Mohawk Tribe, claiming the group's status as a sovereign nation meant the patents could not be reviewed by the U.S. patent office. Allergan said the move was justified because the same patents were already being reviewed in federal court, but critics said it was a cynical attempt to prolong the company's monopoly on Restasis.

  • Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
    Zacks15 hours ago

    Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

    Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

  • Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall
    Zacks15 hours ago

    Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall

    Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.

  • How Allergan's 'Public Relations Backlash' Deepened This Week
    Investor's Business Daily17 hours ago

    How Allergan's 'Public Relations Backlash' Deepened This Week

    Allergan already faced a "public relations backlash" after transferring the rights to its Restasis patents to a Native American tribe.

  • Barrons.com17 hours ago

    And For Allergen's Next Trick..Filling a $1.5 Billion Hole?

    Not even Botox can wipe away the worry lines that followed Allergan’s (AGN) recent patent loss. Yesterday, a federal district court judge invalidated some of the patents protecting blockbuster dry-eye treatment Restasis, opening the door for generic rivals that could shove sales of Allergan’s second-biggest selling drug righ off a cliff. Many argue that the event is already baked into Allergan’s stock price, as is the public relations backlash from the controversial deal the drug maker struck last month with the Saint Regis Mohawk Tribe of upstate New York to block its Restasis patents from scrutiny by the U.S. Patent and Trade Office.

  • Bloomberg20 hours ago

    Here's How Drug Companies Game the Patent System

    Only Congress can rewrite the laws that keep prices high. Ask the judge.

  • TheStreet.com23 hours ago

    Allergan Is the Cheapest Big-Cap Drug Stock in the Universe: Jim Cramer

    Cramer says he'll buy more shares of the lackluster drugmaker for his charitable trust if the price drops below $200.

  • 3 Dividend Healthcare Stocks
    Motley Fool23 hours ago

    3 Dividend Healthcare Stocks

    If you're on the hunt for outstanding healthcare dividend stocks, Allergan, Bristol-Myers Squibb, and McKesson need to be on your radar.

  • The Wall Street Journal2 days ago

    [$$] Allergan Loses Patent Fight in Federal Court

    A U.S. District Court ruled patents for one of Allergan’s best-selling drugs are invalid, potentially opening the door for generic competition.

  • Allergan Tanks After Judge Invalidates Restasis Patents
    Investor's Business Daily2 days ago

    Allergan Tanks After Judge Invalidates Restasis Patents

    Allergan tanked Monday after a federal judge invalidated patents covering eye-drug Restasis.

  • Barrons.com2 days ago

    Allergan Loses a Patent Battle…Has It Lost the War?

    With its stock price in a free fall after a federal judge invalidated patents covering the dry eye drug Restasis, what’s next for Allergan (AGN). ... a generic version of Restasis has not yet been approved and even if a generic were approved within that time frame, a launch prior to the conclusion of that appeal would be considered ''at-risk''. Today’s court ruling is the latest development in the legal dispute pitting Allergan against a group of generic drug makers led by Teva Pharmaceutical Industries (TEVA) and Mylan (MYL).

  • MarketWatch2 days ago

    Allergan patent suit loss sends stock down 5%

    Allergan had made a widely-criticized agreement with an American Indian tribe to defend a key product. This lawsuit could render it all moot.

  • Reuters2 days ago

    U.S. judge in Texas invalidates Allergan patents on Restasis

    Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries Ltd. The ruling could enable the generic drug companies to sell their own versions of Restasis, which generated around $1.5 billion in sales for Allergan last year and accounted for more than 10 percent of the company's revenue.

  • MarketWatch2 days ago

    Allergan stock drops 5% after judge decides against company on key dry eye product

    Allergan PLC shares dropped 5% in extremely heavy afternoon trade Monday after a Texas district court judge ruled against the company in a patent lawsuit regarding the company's key billion-dollar dry ...

  • TheStreet.com2 days ago

    Allergan Update; Fixed Income: Doug Kass' Views

    Doug Kass shares his thoughts on Allergan and fixed income.

  • The Wall Street Journal2 days ago

    [$$] Mylan Calls Allergan’s Patent Sale to Indian Tribe a ‘Sham’

    Generic-drug company Mylan has fired back at rival Allergan’s attempt to shield its top-selling eye medication from competition by transferring the patents to an Indian tribe.

  • Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
    Zacks5 days ago

    Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

    Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

  • 3 Healthcare Value Stocks
    Motley Fool5 days ago

    3 Healthcare Value Stocks

    Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.

  • Non-Alcoholic Steatohepatitis 2017 Progress Update
    Zacks6 days ago

    Non-Alcoholic Steatohepatitis 2017 Progress Update

    Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • Reuters6 days ago

    Allergan settles with one of four companies contesting Restasis patent

    Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc are still contesting those patents in U.S. District Court in Marshall, Texas.

  • Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up
    Zacks6 days ago

    Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

    Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

  • Allergan will repeal Restasis patent decision
    CNBC Videos2 days ago

    Allergan will repeal Restasis patent decision

    CNBC's Meg Tirrell reports on the latest developments on a federal court invalidating Allergan's eye drug patents.

  • Allergan's Restasis patents invalidated by federal judge
    CNBC Videos2 days ago

    Allergan's Restasis patents invalidated by federal judge

    CNBC's Meg Tirrell reports on Allergan sinking after a federal judge invalidates patents on their drug Restasis.

  • Trump to scrap a crucial part of Obamacare
    Yahoo Finance Video5 days ago

    Trump to scrap a crucial part of Obamacare

    The White House is eliminating a crucial part of the Affordable Care Act. President Donald Trump wants to immediately stop payments to insurers. The administration said the government cannot legally continue to make payments. Yahoo Finance’s Alexis Christoforous and Rick Newman figure out how this will impact the insurance industry and patients.